RemedyRepack Glipizide 2.5mg ER Tablets: Failed Dissolution Risk
RemedyRepack recalls Glipizide 2.5mg ER tablets with failed dissolution specifications. These tablets may not release medication properly, risking ineffective treatment. Contact for return instructions.
Lower-risk recall
Failed Dissolution Specifications
Contact the company
What happened, in plain English
RemedyRepack is recalling Glipizide 2.5 mg ER tablets that failed dissolution tests. This means the medication might not work as intended, potentially leading to uncontrolled blood sugar levels. Read more at govinfonow.com/recall/42046-remedyrepack-glipizide-2-5mg-er-tablets-failed-dissolution-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/42046-remedyrepack-glipizide-2-5mg-er-tablets-failed-dissolution-risk · Updated October 8, 2026 · FDA enforcement record: FDA #D-0482-2017
Cite this page
“RemedyRepack Glipizide 2.5mg ER Tablets: Failed Dissolution Risk.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/42046-remedyrepack-glipizide-2-5mg-er-tablets-failed-dissolution-risk. Based on FDA recall #D-0482-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0482-2017%22&limit=1).
Why it’s dangerous
The tablets failed dissolution specifications, meaning they may not release medication correctly in the body. This could lead to ineffective blood sugar control. However, the recall does not mention serious injury risks.
Who’s affected
People taking Glipizide for diabetes who own the recalled tablets. Those with diabetes are most at risk if the medication doesn't work properly.
How to tell if you have this one
Check for the NDC 52125-0764-02 or 00591-0900-30 on the packaging. The lot number B0129373-021916 and expiration date 10/17 are also indicators of the recalled product.
- Brand
RemedyRepack- Category
Drug
What to do — step by step
Check Product Details
Look for the NDC 52125-0764-02 or 00591-0900-30 on the packaging.
Where it went and when
Where it was distributed
Distributed in Florida.
FDA distribution: “Product was distributed to a sold customer in FL.” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Florida.
Recall timeline
FDA terminated this recall 3 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0482-2017 (February 7, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0482-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.